Clovis Oncology Stock News

Clovis Oncology Inc. (NASDAQ:CLVS) shares, rose in value on Thursday, 12/16/21, with the stock price down by -3.17% to the previous days close as strong demand from buyers drove the stock to $2.75. Actively observing the price movement in the last trading, the stock closed the session at $2.84, falling within a range of $2.72 Is Now A Good Time To Invest In Clovis Oncology Inc. (NASDAQ: CLVS)? Read More »

If you''re a trend trader, consider that the strongest clear trend on the daily chart exists on the 20 day timeframe. The post Clovis Oncology Inc (CLVS): Price Now Near $2.66; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .

Wall Street brokerages expect Clovis Oncology (NASDAQ:CLVS) to announce earnings of ($0.56) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Clovis Oncologys earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.32). Clovis Oncology reported earnings per share of []

Clovis Oncology Inc. (NASDAQ:CLVS) price on Thursday, December 09, fall -7.91% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.91. A look at the stocks price movement, the close in the last trading session was $3.16, moving within a range at $2.905 and $3.1592. The beta value Clovis Oncology Inc. (CLVS) Outlook: Looking Back For Insights Read More »

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Goldman Sachs Group Inc. lifted its position in shares of Clovis Oncology (NASDAQ:CLVS) by 25.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 361,026 shares of the biopharmaceutical companys stock after buying an additional 73,877 shares during the quarter. Goldman Sachs Group Inc.s []

Global Ovarian cancer drug report deals with the new business challenges and investment research on the market which includes market attributes, industry structure, and competitive scenario, the problems, desire concepts, together with business strategies and market effectiveness. This is the

In today’s recent session, 1.09 million shares of the Clovis Oncology Inc. (NASDAQ:CLVS) have been traded, and its beta is 1.60. Most recently the company’s share price was $3.08, and it changed around -$0.04 or -1.31% from the last close, which brings the market valuation of the company to $418.70M. CLVS at last check was … If You’re A Risk-Taking Investor, Clovis Oncology Inc. (NASDAQ: CLVS) Is Worth Taking A Chance On. Read More »

Clovis Oncology Inc. (NASDAQ:CLVS)’s traded shares stood at 1.56 million during the latest session, with the company’s beta value hitting 1.62. At the last check today, the stock’s price was $3.53, to imply a decrease of -2.75% or -$0.1 in intraday trading. The CLVS share’s 52-week high remains $11.10, putting it -214.45% down since that … Should Clovis Oncology Inc. (NASDAQ: CLVS) Rally After -214.45% Drop From High? Read More »

Clovis Oncology Inc. (NASDAQ:CLVS) price closed lower on Tuesday, November 16, dropping -1.03% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2021 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of -16.67% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

If you're like most traders right now, you're looking for an edge.… The post Best Penny Stocks To Buy For A Short Squeeze?

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.